Open-label, Multicenter, Non-Comparative Prospective Study to Assess the Safety of Individualized Combination Therapy With Ribavirin And Peginterferon alfa-2a (40 kD) in Patients With Chronic Hepatitis C (CHC) (MASTER study)

Trial Profile

Open-label, Multicenter, Non-Comparative Prospective Study to Assess the Safety of Individualized Combination Therapy With Ribavirin And Peginterferon alfa-2a (40 kD) in Patients With Chronic Hepatitis C (CHC) (MASTER study)

Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 10 Jun 2016

At a glance

  • Drugs Peginterferon alfa-2a (Primary) ; Ribavirin (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions
  • Acronyms MASTER
  • Sponsors Roche
  • Most Recent Events

    • 22 Jul 2011 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 15 Feb 2011 New source identified and integrated (ClinicalTrials.gov record).
    • 09 Dec 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top